Competition opens for wearables capable of detecting blood-alcohol levels

The National Institute on Alcohol Abuse and Alcoholism is holding a competition to develop technology for wearable devices to measure blood-alcohol levels in real time. The first-place prototype winners will be awarded $200,000, with $100,000 going to second place.

“I expect tangible breakthroughs in real-time alcohol-sensing technology through this competition,” said NIAAA Director George F. Koob, MD. “Creative solutions could include the adaptation and miniaturization of technologies such as spectroscopy or wave technology or other designs. I think we can build on the success of our first challenge, which made important strides in improving transdermal alcohol sensing.”

The guidelines for the ideal prototype state that the ideal device would be able to measure alcohol concentration in blood or interstitial fluid, instead of the conventional technology that measures through sweat or vapor. Designed to find a tool to help researchers is measuring more accurate data, the competition hopes to eventually aid in the understanding and treatment of patients with alcohol abuse disorders as well as liver disease and HIV/AIDS.

“We have learned that there is real interest in the private sector around wearable alcohol biosensors, and that innovation using distinct means of alcohol detection are on the horizon,” said Kathy Jung, PhD, director of NIAAA’s Division of Metabolism and Health Effects and co-leader of the competition. “We want to continue to harness the power of the private sector, because if alcohol biosensors become a part of the ‘wearable toolbox,’ tangible new opportunities will become available that will profoundly affect the field of alcohol research.”

Submissions of a wearable prototype that provides data functionality and photos/videos will be accepted until May 15, 2017. Judging will conclude July 26, 2017, with winners announced in August 2017.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.